STIM1 and Alzheimer disease: Altogether, our findings identify astrocyte Ca2+ hypoactivity as an early marker of defective somatosensory function in AD and point to STIM1 as a potential primary target for the development of novel AD therapies based on the modulation of astrocyte Ca2+ signaling.